The drug--drug interaction between proton pump inhibitors and clopidogrel

Lau, Wei C.
March 2009
CMAJ: Canadian Medical Association Journal;3/31/2009, Vol. 180 Issue 7, p699
Academic Journal
In this article the authors discuss the study to examine a cytochrome P450 2C19-dependent drug-drug interaction between proton pump inhibitors and clopidogrel. They mention that the study was adapted for the imbalances in covariates such as cardiovascular comorbidities and evidence-based cardiovascular medications. However, they note that the study lack of data on patient compliance with antiplatelet therapy and did not account for ethnicity.


Related Articles

  • Clopidogrel interactions not clear cut. Aley, Christopher // Pulse;2/18/2009, Vol. 69 Issue 5, p16 

    Two letters to the editor are presented in response to the article "GPs urged to review clopidogrel patients after PPI interaction warning," which includes the effect of clopidogrel to the cytochrome P450 system and the confusion over the theoretical advantage of pantoprazole affecting the...

  • Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve. Niioka, Takenori; Uno, Tsukasa; Yasui-Furukori, Norio; Shimizu, Mikiko; Sugawara, Kazunobu; Tateishi, Tomonori // European Journal of Clinical Pharmacology;Oct2006, Vol. 62 Issue 10, p855 

    The purpose of this study is to evaluate whether a simple formula using limited blood samples can predict the area under the plasma rabeprazole concentration-time curve (AUC) in co-administration with CYP inhibitors. A randomized double-blind placebo-controlled crossover study design in three...

  • Tailoring Antiplatelet Therapy Based on Pharmacogenomics. Bhatt, Deepak L. // JAMA: Journal of the American Medical Association;8/26/2009, Vol. 302 Issue 8, p896 

    The article discusses research on the genetic response of patients to the antiplatetet drug clopidogrel. It references the study "Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy," by A. R. Shildiner and colleagues, published...

  • Treatment with clopidogrel and PPI increased risk for adverse outcomes following acute coronary syndrome. Adams, Stacey L.; Harris, Jason; Southall, Jennifer // Hem/Onc Today;4/10/2009, Vol. 10 Issue 7, p29 

    The article discusses a study of the adverse outcomes among patients given the antiplatelet drug clopidogrel with or without proton pump inhibitor (PPI) following hospitalization for acute coronary syndrome (ACS).

  • SCAI: Evidence of interaction between proton pump inhibitors, clopidogrel not sufficient to change practice. Raible, Eric // Cardiology Today;Jan2009, Vol. 12 Issue 1, p18 

    The article reports that conflicting results from two studies of antiplatelet drug clopidogrel and proton pump inhibitors prompted the Society for Cardiovascular Angiography and Interventions (SCAI) to issue a statement clarifying the implications.

  • Individualized Therapy for Gastroesophageal Reflux Disease. Furuta, Takahisa; Sugimoto, Mitsushige; Shirai, Naohito // Molecular Diagnosis & Therapy;2012, Vol. 16 Issue 4, p223 

    The main therapeutic agent for gastroesophageal reflux disease (GERD) is a proton pump inhibitor (PPI). Plasma levels and the acid inhibitory effect of PPIs depend on the activity of cytochrome P450 (CYP) 2C19, which is polymorphic. Genotypes of CYP2C19 are classified into three groups: rapid...

  • A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants*. Sim, Sarah C.; Risinger, Carl; Dahl, Marja-Liisa; Aklillu, Eleni; Christensen, Magnus; Bertilsson, Leif; Ingelman-Sundberg, Magnus // Clinical Pharmacology & Therapeutics;Jan2006, Vol. 79 Issue 1, p103 

    Background and Objective: Many drugs, including proton pump inhibitors and certain antidepressants, are metabolized by the polymorphic cytochrome P450 (CYP) 2C19 enzyme. A significant portion of extensive metabolizers do not reach appropriate drug levels, and our objective was to investigate any...

  • Interaction between clopidogrel and proton pump inhibitors: A clinical overview. Nagavi, Jinesh B.; Gurupadayya, B. M. // International Journal of Pharmacy;Jul2014, Vol. 4 Issue 3, p141 

    Most proton pump inhibitors inhibit the bioactivation of clopidogrel to its active metabolite. The clinical significance of this drug interaction is unknown. Over recent years there has been much debate about whether some or all proton pump inhibitors might reduce the effectiveness of...

  • Inter-Individual Variation in Pharmacokinetics of Proton Pump Inhibitors in Healthy Indian Males. Rani, Shubha; Padh, Harish // Indian Journal of Pharmaceutical Sciences;2006, Vol. 68 Issue 6, p754 

    Proton pump inhibitors have revolutionized the management of acid-peptic disorders in recent years. They have a broadly similar mechanism of action and are extensively metabolized in the liver via cytochrome P450 2C19 and 3A4 enzymes. A wide inter-individual variability in pharmacokinetics due...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics